stockmarketproxy
/
HALONasdaq SEC EDGAR

HALOZYME THERAPEUTICS, INC.

Biological Products, (No Diagnostic Substances)·SAN DIEGO, CA·FY end 12/31·CIK 1159036
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$1.4B$1.0B$829.3M$660.1M$443.3M
Gross Profit——————
Operating Income$469.0M$551.5M$337.6M$267.5M$275.9M
Net Income$316.9M$444.1M$281.6M$202.1M$402.7M
Operating CF$651.6M$479.1M$388.6M$240.1M$299.4M
Capex$7.0M$10.7M$15.3M$4.8M$1.5M
Free Cash Flow$644.6M$468.4M$373.3M$235.3M$298.0M
Buybacks$342.4M$250.0M$402.4M$109.8M$150.0M
Dividends——————
Gross Margin——————
Operating Margin33.6%54.3%40.7%40.5%62.2%
Net Margin22.7%43.7%34.0%30.6%90.8%
FCF Margin46.2%46.1%45.0%35.6%67.2%
R&D / Revenue—7.8%9.2%10.1%8.0%
Effective Tax32.1%20.3%19.2%18.8%62.0%
Debt / Equity87.798.2835.7817.587.99
Buybacks / FCF53.1%53.4%107.8%46.7%50.3%

Peer comparison

Biological Products, (No Diagnostic Substances) · 5 peers
CEO Pay Ratio
HALO
—
EXEL
81:1
GILD
119:1
BIIB
113:1
PCVX
48:1
IBRX
69:1
CEO total comp
HALO
$23M
EXEL
$33M
GILD
$28M
BIIB
$24M
PCVX
$14M
IBRX
$13M
Net Margin
HALO
22.7%
EXEL
33.7%
GILD
28.9%
BIIB
13.1%
PCVX
—
IBRX
-310.2%